Abstract:“We now have a name for the disease caused by coronavirus and itu0027s COVID-19”, said Dr Tedros Adhanom Ghebreyesus, Director-General of WHO on Feb 11, 2020.1 WHO recently updated the name novel coronavirus pneumonia, previously named by Chinese scientists,2 to coronavirus disease 2019 (COVID-19). More attention should be paid to comorbidities in the treatment of COVID-19. In the literature, COVID-19 is characterised by the symptoms of viral pneumonia such as fever, fatigue, dry cough, and lymphopenia. Many of the older patients who become severely ill have evidence of underlying illness such as cardiovascular disease, liver disease, kidney disease, or malignant tumours.3, 4, 5 These patients often die of their original comorbidities; we therefore need to accurately evaluate all original comorbidities of individuals with COVID-19. In addition to the risk of group transmission of an infectious disease, we should pay full attention to the treatment of the original comorbidities of the individual while treating pneumonia, especially in older patients with serious comorbid conditions. Not only capable of causing pneumonia, COVID-19 may also cause damage to other organs such as the heart, the liver, and the kidneys, as well as to organ systems such as the blood and the immune system.3, 4, 5 Patients eventually die of multiple organ failure, shock, acute respiratory distress syndrome, heart failure, arrhythmias, and renal failure.5, 6 We should therefore pay attention to potential multi-organ injuries and the protection and prevention thereof in the treatment of COVID-19. • View related content for this article We took over a ward for the centralised treatment of severely ill patients in Wuhan Tongji Hospital. 60 patients were classified into three types during their treatment. 13 [22%] of 60 patients mainly had pneumonia and were classified as type A. Basic treatments were provided, such as antivirals, antibiotics, oxygen therapy, and glucocorticoids. 33 (55%) of 60 patients were type B, with disease that manifested with different degrees of pneumonia, accompanied by serious comorbidities. For patients classified as type B, we continued to monitor the changes of comorbidities while managing the pneumonia, carrying out individual evaluations and developing specific treatment plans, including antihypertensives, hypoglycaemic therapy, and continuous renal replacement therapy. 14 (23%) of 60 patients were critically ill and were classified as type C. Patients classified as type C had disease that was considered to have developed from the aggravation of disease seen either in type A or type B, when early therapeutic effects for type A disease were unsatisfactory (resulting in multiple organ injuries), or when disease associated with type B became aggravated and the patientu0027s condition deteriorated from their original comorbidities (leading to multiple organ failure). Attention should be paid to organ function in these critically ill patients and necessary protective measures, including mechanical ventilation, glucocorticoids, antivirals, symptomatic treatments, and anti-shock therapy. We believe that the classification of COVID-19 in severe patients could help in individual evaluation of the disease and would provide effective triage for the treatment and management of individual patients. We declare no competing interests.

Comorbidities and Multi-Organ Injuries in the Treatment of COVID-19

Comorbidities and multi-organ injuries in the treatment of COVID-19

The mechanism of multiple organ dysfunction syndrome in patients with COVID-19

The Mechanism of Multiple Organ Dysfunction Syndrome in Patients with COVID‐19

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China

Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis

Current epidemiological and clinical features of COVID-19; a global perspective from China.

Comorbidity and its Impact on Patients with COVID-19

Risk factors associated with fatal outcomes of novel coronavirus infection pneumonia (COVID-19): A systematic review and meta-analysis

Clinical characteristics of 2019 novel coronavirus pneumonia and risk factors for severe cases: a meta-analysis involving 5,729 patients

Eleven Faces of Coronavirus Disease 2019

COVID-19 with Different Severities: A Multicenter Study of Clinical Features

The Clinical Characteristics and Prognosis of COVID-19 Patients with Comorbidities: a Retrospective Analysis of the Infection Peak in Wuhan.

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment

Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations

Prevalence, Clinical Characteristics and Outcomes of COVID-19 Combined with Cardiac Injury

Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis

Clinical features of COVID-19 patients with comorbid coronary heart disease

Cardiac injuries in coronavirus disease 2019 (COVID-19)